Cantor Fitzgerald Forecasts Omeros FY2026 Earnings

Omeros Co. (NASDAQ:OMER) – Analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for Omeros in a report released on Monday, June 9th. Cantor Fitzgerald analyst O. Brayer expects that the biopharmaceutical company will earn ($1.14) per share for the year. The consensus estimate for Omeros’ current full-year earnings is ($3.09) per share.

OMER has been the topic of a number of other research reports. HC Wainwright began coverage on shares of Omeros in a research report on Tuesday. They set a “buy” rating and a $9.00 price objective on the stock. D. Boral Capital reissued a “buy” rating and set a $36.00 price objective on shares of Omeros in a research report on Tuesday, May 13th. Wall Street Zen cut shares of Omeros from a “hold” rating to a “sell” rating in a research report on Friday, June 6th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Omeros in a research report on Friday, May 16th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Omeros has a consensus rating of “Moderate Buy” and a consensus price target of $18.00.

Omeros Trading Down 6.7%

Shares of Omeros stock opened at $3.62 on Tuesday. The business has a 50-day moving average price of $5.23 and a two-hundred day moving average price of $7.85. Omeros has a 1-year low of $2.97 and a 1-year high of $13.60. The company has a market cap of $212.11 million, a P/E ratio of -1.57 and a beta of 2.20.

Omeros (NASDAQ:OMER) last posted its quarterly earnings data on Thursday, May 15th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.05).

Hedge Funds Weigh In On Omeros

Large investors have recently added to or reduced their stakes in the business. Truvestments Capital LLC lifted its position in Omeros by 116.5% in the 4th quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 1,669 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in Omeros by 79.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company’s stock valued at $44,000 after acquiring an additional 1,972 shares in the last quarter. Quantbot Technologies LP bought a new position in Omeros in the 4th quarter valued at about $46,000. Picton Mahoney Asset Management lifted its position in Omeros by 692.5% in the 4th quarter. Picton Mahoney Asset Management now owns 5,040 shares of the biopharmaceutical company’s stock valued at $50,000 after acquiring an additional 4,404 shares in the last quarter. Finally, GAMMA Investing LLC lifted its position in Omeros by 14,486.3% in the 1st quarter. GAMMA Investing LLC now owns 7,439 shares of the biopharmaceutical company’s stock valued at $61,000 after acquiring an additional 7,388 shares in the last quarter. Institutional investors own 48.79% of the company’s stock.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.